Quick Answer
Regen BioPharma Inc reported Net Income Loss of -$1.27 million for the year ending 2025.
- Regen BioPharma Inc showed a decrease of -90.7% in Net Income Loss from 2024 to 2025.
- This data is from Regen BioPharma Inc's annual report (Form 10-K), filed with the SEC on December 30, 2025.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), Regen BioPharma Inc's Net Income Loss has declined by 259.0%.
- Historical annual values: Fiscal year 2025: -$1.27 million | Fiscal year 2024: -$668.3 thousand | Fiscal year 2023: $1.16 million | Fiscal year 2022: $2.44 million | Fiscal year 2021: -$6.77 million | Fiscal year 2020: $3.41 million | Fiscal year 2019: -$2.62 million | Fiscal year 2018: -$4.72 million | Fiscal year 2017: -$5.84 million | Fiscal year 2016: -$7.75 million | Fiscal year 2015: -$11.20 million | Fiscal year 2014: -$756.4 thousand | Fiscal year 2013: -$355.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: